The purpose of this study is to demonstrate that the new yellow fever vaccine is as safe and effective as the currently licensed yellow fever vaccines.
Eligibility criteria include age 18–59 inclusive, not pregnant or breastfeeding, no history of prior flavivirus infection or vaccination, no history of immune compromise, no history of thymic disease orthymectomy.
Study requirements: one vaccination visit, 9–10 follow-up visits over five years, blood sampling, symptom diary.
Compensation: $870–$950 depending on visits completed.
To obtain more information, contact the Center for Immunization Research recruitment department at 410-955-7283 or visit the CIR yellow fever study website.
PI: Dr. Kawsar Talaat